This suggests that CAR-iNKT cells may be better suited than CAR-T for tumor cell types proven to express CD1d and provide rationale for treating patients with tumors positive for both the CAR target and CD1d with CAR-iNKT cells. This evidence concerns the gene CD1D and neoplasm.